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Background:  Concentrations of ST2 (a biomarker of cardiomyocyte stretch) are prognostic in patients with heart failure (HF). Little is known 
about the role of soluble ST2 (sST2) measurement in patients with advanced-stage HF, such as those requiring therapy guided by pulmonary artery 
catheterization.
Methods:  Patients with American Heart Association Stage D HF were enrolled after admission to a Cardiac Intensive Care Unit for treatment guided 
by invasive monitoring. Samples for measurement of sST2 concentration (Presage ST2®, Critical Diagnostics) were collected twice daily for the first 
48 hours, with corresponding filling pressures noted. Response to tailored therapy based on standard criteria as well as event-free survival (death, 
left ventricular assist device [LVAD] implantation, heart transplantation) at 90 days were correlated to highest ST2 values.
Results:  30 subjects (mean age 58 years, mean ejection fraction 25%) were studied. Concentrations of sST2 were higher among those whose 
central venous pressure ([CVP], 225.3 vs 104.6 ng/mL; p = .003) and pulmonary capillary wedge pressure ([PCWP], 181.7 vs 88.2 ng/mL; p=.05) 
did not reach filling pressure goals within 48 hours. As a predictor of failure to achieve CVP goals by 48 hours, sST2 had an area under the curve 
of 0.82 (p < .001), while as a predictor of failed achievement of PCWP goals, sST2 had an area under the curve of 0.68 (p =.06). Significantly 
higher sST2 levels were observed during the first 48 hours of tailored therapy in patients who experienced an event (186.7 vs 92.2 ng/mL; p=.01). 
In Kaplan-Meier analysis, an sST2 level >104 ng/mL identified a higher rate of events compared to those below (log rank p=.01), and in an age-
adjusted Cox proportional hazards model, an sST2 >104 ng/mL predicted complications (Hazard Ratio = 5.5; 95% CI 1.2-24.6; p =.03).
Conclusions:  In patients with American Heart Association Stage D HF undergoing therapy guided by invasive monitoring, elevated concentrations 
of sST2 are associated with failed achievement of filling pressure goals, and predict impending death, LVAD placement or heart transplantation. 
Measurement of sST2 may therefore be useful to assist in care decisions in advanced stage HF patients.
